Aerovance

Aerovance Inc. was a clinical-stage biopharmaceutical company that operated from 2004 until it became defunct. The company was established as a spin-out from Bayer Pharmaceuticals Corp. and was headquartered in Berkeley, California. Aerovance's primary focus was on the development and commercialization of therapies for respiratory and inflammatory diseases, with a pipeline targeting conditions like uncontrolled asthma, cystic fibrosis, and eczema.

The company's business model centered on advancing its portfolio of drug candidates through clinical trials to either seek strategic partnerships with large pharmaceutical companies for late-stage development and commercialization or to eventually sell the company. Aerovance successfully raised significant capital to fund its operations, securing a total of $98 million over five funding rounds from institutional investors including Apax Partners, Clarus Ventures, Alta Partners, and Lehman Brothers. Notable funding events included a $60 million Series C round completed in 2007 and a $38 million equity financing in 2009 to support a crucial Phase IIb trial.

Aerovance's lead product candidate was Aerovant™ (pitrakinra), a recombinant human IL-4 variant designed as a potent inhibitor of both IL-4 and IL-13, cytokines critical to the inflammatory cascade in asthma. Delivered as an inhaled dry powder, Aerovant aimed to provide a non-steroidal treatment for patients with uncontrolled asthma, particularly those with eosinophilic asthma. The company advanced Aerovant into a large-scale Phase IIb clinical trial, called AeroTrial™, across 75 sites in the U.S. and Europe. Results announced in 2010 showed a significant reduction in asthma exacerbations for a subset of patients with eosinophilic asthma. Other key products in its pipeline included Aerolytic™, a serine protease inhibitor for cystic fibrosis, and Aeroderm™, a formulation for eczema.

The leadership team included President and CEO Mark Perry, who guided the company's strategy through challenging financial markets, and Chief Medical Officer Dr. Babatunde A. Otulana, who brought extensive experience in pulmonary drug development. Despite promising clinical data for Aerovant and a robust development plan, the company ultimately ceased operations.

Keywords: Aerovance, biopharmaceutical, respiratory diseases, inflammatory diseases, asthma treatment, pitrakinra, Aerovant, clinical trials, cystic fibrosis, eczema, IL-4 inhibitor, IL-13 inhibitor, Bayer spin-out, venture capital, drug development, eosinophilic asthma, inhaled therapeutics, biopharmaceutical financing, defunct biotech, Mark Perry